Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

rate, the Company has proposed an amended trial to continue its interest in the relapsed setting.

An agreement has been reached with the FDA on modifications to Vion Study CLI-037. The revised study includes a lower dose of Cloretazine(R) (VNP40101M) in the experimental arm of the trial and prophylactic therapy with antibiotics, antifungals and growth factors for all patients. In order to maintain the Special Protocol Assessment (SPA) with the FDA for this trial, the next step is to submit an SPA to the FDA with these modifications before recommencing the trial.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center at San Antonio, and lead investigator on the Cloretazine(R) clinical program stated, "Cloretazine(R) has recently shown very significant single agent activity in a the difficult to treat elderly AML patient population. It is important that we now establish the optimal dosing schedule in combination with other chemotherapeutic agents, such as cytarabine." He concluded, "Modifications to this Phase III trial in patients with relapsed AML will allow us to examine a combination schedule that should maintain the activity observed in the initial portion of the study with an acceptable marrow toxicity profile."

The Company also announced plans to file an abstract on data from Vion Study CLI-037 for the Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in June 2008.

Ann Cahill, Vice President, Clinical Development, commented, "Cloretazine(R) (VNP40101M) is an active agent in AML, and we continue to believe that it will have clinical utility in both the frontline and second line settings, as either a single agent or in combination with other therapies."

The Company has announced previously that it plans to file a New Drug Application with the FDA in 2008 based on a pivotal Phase II study of Cloretazine(R) (VNP40101M) as a single agent in eld
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... 2014  Aptuit LLC announces that Aptuit SSCI, ... , has enhanced its capabilities in the areas ... large molecules, including biologic drugs, metabolites, and polymers, ... mass spectrometer. In making the announcement, ... "The expanded large molecule capability enhances our early ...
(Date:8/21/2014)... Texas , Aug. 21, 2014  Vermillion, Inc. ... focused on gynecologic cancers and women,s health, has appointed ... Sales and Managed Markets. Ms. Bauzon has ... and expanding payer coverage for laboratory services companies. She ... recently with PerkinElmer, Inc., where she held the position ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... Challenges Explorations to support bold, ... diseases, SEATTLE, March 3 The Bill & Melinda ... accept grant,proposals for the first funding round of Grand Challenges ... globe pursue,ideas that have never before been tested for solving ...
... company developing,breakthrough cardiovascular molecular imaging agents for the ... safety results,for CardioPET, the company,s lead product., ... and dosimetry,of CardioPET as a PET tracer for ... Artery Disease (CAD). Dr. David Elmaleh, Chairman,and scientific ...
Cached Medicine Technology:Gates Foundation Seeks Proposals for Innovative Global Health Research 2Gates Foundation Seeks Proposals for Innovative Global Health Research 3FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET) 3
(Date:8/22/2014)... This report studies the "Sample Preparation Market ... (Tubes), Kits (Isolation, Purification), By Application (Genomics, Proteomics), ... to 2018" This market was valued at $4,254.8 ... at a CAGR of 5.9% from 2013 to ... Browse 98 market data Tables and 23 Figures ...
(Date:8/22/2014)... With the stage set for the ... Expo - which will be held in Boston August ... in its online opinion section, Podium. The op-ed ... co-authored by Steven C. Anderson, IOM, CAE, president & ... the MCPHS University School of Pharmacy – Worcester/Manchester. ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
(Date:8/22/2014)... Indiana (PRWEB) August 22, 2014 The ... Toyota Indiana is on the grow again. ... 300 jobs by summer 2016 to boost production of ... will bring Toyota Indiana’s overall investment to $4 billion. ... North America while providing additional flexibility to adjust its ...
(Date:8/22/2014)... Medicine team has found that targeted automated alerts ... infections in hospital patients with urinary catheters. In ... simplified, the rate of improvement dramatically increased. , ... need urinary catheters in the first place and ... catheters that have not been removed within a ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3
... School of Massage, taking the National Certification Examination for Therapeutic Massage ... points higher than the national average. , ... Atlanta, ... Massage (atlantaschoolofmassage.com), taking the National Certification Examination for Therapeutic Massage for ...
... Recall included Famous Amos and Keebler peanut butter cookies; ... ; toll now stands at 452 sick in 43 ... , , FRIDAY, Jan. 16 (HealthDay News) -- Cereal giant ... as U.S. health officials expanded their investigation into peanut ...
... Database, 85 percent of hospitals in the contracting phase of an IT ... when CCHIT released its first acute care or inpatient certified products. ... ... HIMSS Analytics Database, 85 percent of hospitals in the contracting phase of ...
... products; toll now stands at 452 sick in 43 states ... Jan. 16 (HealthDay News) -- U.S. health officials said Friday ... contaminated with salmonella, as the toll from the outbreak climbed ... Canada, and possibly six deaths. , , U.S. Food and ...
... Group announces a former Harris Interactive executive has joined to ... to announce the appointment of J. Scott Moller, M.S. as ... Mr. Moller has a BA in Economics and Political Science ... from the University of Rochester . Before joining ...
... trumps violent content among gamers, study finds , , FRIDAY, ... video game, not the violence or gore it depicts, that ... Bloodiness, in fact, actually detracts from a game,s "fun factor" ... of Rochester and Immersyve Inc., a firm that researches gamers, ...
Cached Medicine News:Health News:Atlanta School of Massage Grads Beat National Test Scores By Wide Margin 2Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 2Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 3Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 4Health News:85 Percent of Hospitals Select CCHIT Certified Products 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 3Health News:85 Percent of Hospitals Select CCHIT Certified Products 4Health News:85 Percent of Hospitals Select CCHIT Certified Products 5Health News:FDA Widens Peanut Butter-Salmonella Probe 2Health News:FDA Widens Peanut Butter-Salmonella Probe 3Health News:KJT Group L.L.C. Continues Solid Growth 2Health News:Game, Not Gore, Keeps Video Players Playing 2
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated....
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: